PDCD1 and lymphoma: Combined treatment with ADU-S100 and the programmed cell death protein 1 (PD-1) inhibitor spartalizumab also shows a favourable safety profile in patients with advanced/metastatic solid tumours or lymphoma (Meric-Bernstam et al., 2022b).